[go: up one dir, main page]

WO1996040250A3 - Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation - Google Patents

Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation Download PDF

Info

Publication number
WO1996040250A3
WO1996040250A3 PCT/US1996/010216 US9610216W WO9640250A3 WO 1996040250 A3 WO1996040250 A3 WO 1996040250A3 US 9610216 W US9610216 W US 9610216W WO 9640250 A3 WO9640250 A3 WO 9640250A3
Authority
WO
WIPO (PCT)
Prior art keywords
platelet
specific chimeric
immunoglobulin
methods
chimeric immunoglobulin
Prior art date
Application number
PCT/US1996/010216
Other languages
English (en)
Other versions
WO1996040250A2 (fr
Inventor
Barry S Coller
David M Knight
Original Assignee
Centocor Inc
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc, Univ New York State Res Found filed Critical Centocor Inc
Priority to AU63323/96A priority Critical patent/AU6332396A/en
Priority to JP9502244A priority patent/JPH11511120A/ja
Priority to EP96922452A priority patent/EP0835135A2/fr
Publication of WO1996040250A2 publication Critical patent/WO1996040250A2/fr
Publication of WO1996040250A3 publication Critical patent/WO1996040250A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des agents qui se lient de manière sélective à la GPIIb/IIIa et au récepteur de vitronectine et peuvent s'utiliser pour réduire ou prévenir les phénomènes d'occlusion, de réocclusion (par ex. fermeture soudaine), de sténose et/ou de récidive de sténose. Dans une variante, une immunoglobuline ou un fragment d'immunoglobuline, telle qu'une immunoglobuline chimérique spécifique des plaquettes ou un de ses fragments comprenant une région non humaine de liaison d'antigène et une région humaine constante, est utilisée dans le procédé.
PCT/US1996/010216 1995-06-07 1996-06-05 Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation WO1996040250A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU63323/96A AU6332396A (en) 1995-06-07 1996-06-05 Platelet-specific chimeric immunoglobulin and methods of use therefor
JP9502244A JPH11511120A (ja) 1995-06-07 1996-06-05 血小板特異的キメラ免疫グロブリン及びその使用方法
EP96922452A EP0835135A2 (fr) 1995-06-07 1996-06-05 Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47552695A 1995-06-07 1995-06-07
US08/475,526 1995-06-07

Publications (2)

Publication Number Publication Date
WO1996040250A2 WO1996040250A2 (fr) 1996-12-19
WO1996040250A3 true WO1996040250A3 (fr) 1997-01-23

Family

ID=23887963

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010216 WO1996040250A2 (fr) 1995-06-07 1996-06-05 Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation

Country Status (7)

Country Link
EP (1) EP0835135A2 (fr)
JP (1) JPH11511120A (fr)
CN (1) CN1186439A (fr)
AU (1) AU6332396A (fr)
CA (1) CA2223885A1 (fr)
NZ (1) NZ513882A (fr)
WO (1) WO1996040250A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
MXPA01005562A (es) * 1998-11-03 2003-08-01 Centocor Inc Anticuerpos y fragmentos de anticuerpos modificados con mayor duracion de actividad.
AUPP783198A0 (en) * 1998-12-21 1999-01-21 Resmed Limited Determination of mask fitting pressure and correct mask fit
CA2371427A1 (fr) * 1999-04-28 2000-11-09 Yamanouchi Pharmaceutical Co., Ltd. Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
EP2404899A1 (fr) * 2004-02-25 2012-01-11 Astellas Pharma Inc. Moyen de contraste pour le dépistage de thrombi
EP2789631A1 (fr) * 2013-04-10 2014-10-15 Synapse B.V. Composés et procédés pour l'inhibition de liaison ICAM-4 vers de l'intégrine plaquettaire alphaIibbeta3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012734A1 (fr) * 1991-01-17 1992-08-06 The Board Of Regents Of The University Of Washington Anticorps contre les facteurs de croissance dans le traitement de la stenose vasculaire
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1995012412A1 (fr) * 1993-11-05 1995-05-11 Centocor, Inc. Immunoglobuline chimerique specifique des plaquettes et son procede d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
WO1992012734A1 (fr) * 1991-01-17 1992-08-06 The Board Of Regents Of The University Of Washington Anticorps contre les facteurs de croissance dans le traitement de la stenose vasculaire
WO1995012412A1 (fr) * 1993-11-05 1995-05-11 Centocor, Inc. Immunoglobuline chimerique specifique des plaquettes et son procede d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARRY S. COLLER ET AL.: "New Antiplatelet Agents: Platelet GPIIb/IIIa Antagonists", THROMBOSIS AND HAEMOSTASIS, vol. 74, no. 1, - July 1995 (1995-07-01), pages 302 - 308, XP002019167 *
WILLIAM E. ROTE ET AL.: "Prevention of Rethrombosis After Coronary Thrombolysis in a Chronic Canine Model. I. Adjunctive Therapy with Monoclonal Antibody 7E3 F(ab')2 Fragment", J. CARDIOVASCULAR PHARMACOLOGY, vol. 23, no. 2, 1994, pages 194 - 202, XP002019168 *

Also Published As

Publication number Publication date
JPH11511120A (ja) 1999-09-28
NZ513882A (en) 2001-09-28
EP0835135A2 (fr) 1998-04-15
AU6332396A (en) 1996-12-30
WO1996040250A2 (fr) 1996-12-19
CN1186439A (zh) 1998-07-01
CA2223885A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
EP1266965A3 (fr) Anticorps de recombinaison pour thérapie humaine
AU2821195A (en) Cross-reacting monoclonal antibodies specific for e-selectin and p-selectin
NZ596723A (en) Human antibodies that bind human il-12 and methods for producing
ZA93779B (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
EP1378525A3 (fr) Anticorps humanisés qui se lient à l'antigène relié par l'anticorp NR-LU-13 et leur utilisation dans des méthodes de ciblage
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
AU1241795A (en) Anti-egf-r/anti-cd3 bispecific monoclonal antibody, method for its production and its use
SG48420A1 (en) Humanized antibodies and uses thereof
GEP20105118B (en) Anti-vegf antibodies
AU3327701A (en) Humanized anti-ccr2 antibodies and methods of use therefor
WO1998018826A3 (fr) Anticorps anti-ccr5 et procedes d'utilisation correspondants
WO1994019466A3 (fr) Nouvelle famille d'anticorps chimeres diriges contre l'antigene carcino-embryonnaire
HU9203370D0 (en) Humanized chimaeric anti-icam-1 antibodies and method for producing them
WO2000005265A3 (fr) Anticorps anti-ccr2 et procedes d'utilisation correspondants
CA2429027A1 (fr) Anticorps contre le recepteur humain h4-1bb
WO1999003987A3 (fr) Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
WO1996040250A3 (fr) Immunoglobuline chimerique specifique des plaquettes et procedes d'utilisation
AU7203194A (en) Bispecific human monoclonal antibodies specific for human immunodeficiency virus
EP0683675A4 (fr) Anticorps monoclonaux humains contre le cytomegalovirus.
CA2126182A1 (fr) Anticorps humanises reagissant avec le gpiib/iiia
AU2547995A (en) Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof
AU3923293A (en) Human monoclonal antibodies and methods for human monoclonal antibody production
IN172885B (fr)
EP1334730A3 (fr) Immunoglobuline chimérique spécifique des plaquettes et procédés de son utilisation
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194312.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996922452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 311914

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 1997 502244

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2223885

Country of ref document: CA

Ref document number: 2223885

Country of ref document: CA

Kind code of ref document: A

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996922452

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996922452

Country of ref document: EP